Form 13-F position report

ACTINIUM PHARMACEUTICALS INC

Reported by MORGAN STANLEY

ATNM CUSIP 00507W206 Manager CIK 0000895421

Reported 2,466 shares, down 3,875 (61.1%) from the prior quarter.

Reported value -55.6%; share count -61.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 2,466 Quarter-end amount reported
Reported value $2,762 Fair value at quarter end
Consecutive quarters held 25 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 184000
2022-03-31 104000
2022-06-30 234000
2022-09-30 370000
2022-12-31 431037
2023-03-31 943914
2023-06-30 444206
2023-09-30 285853
2023-12-31 505698
2024-03-31 553236
2024-06-30 695252
2024-09-30 213739
2024-12-31 272330
2025-03-31 105871
2025-06-30 62580
2025-09-30 7551
2025-12-31 25934
2026-03-31 13533
2026-06-30 6214
2026-09-30 2762

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ACTINIUM PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 2,466 -3,875 (-61.1%) < 0.01% $2,762 2026-11-13
Q2 2026 Reduced 6,341 -7,256 (-53.4%) < 0.01% $6,214 2026-08-13
Q1 2026 Reduced 13,597 -5,472 (-28.7%) < 0.01% $13,533 2026-05-15
Q4 2025 Added 19,069 +14,350 (304.1%) < 0.01% $25,934 2026-02-13
Q3 2025 Reduced 4,719 -39,981 (-89.4%) < 0.01% $7,551 2025-11-14
Q2 2025 Reduced 44,700 -21,058 (-32.0%) < 0.01% $62,580 2025-08-15
Q1 2025 Reduced 65,758 -150,376 (-69.6%) < 0.01% $105,871 2025-05-15
Q4 2024 Added 216,134 +102,443 (90.1%) < 0.01% $272,330 2025-02-14
Q3 2024 Added 113,691 +19,738 (21.0%) < 0.01% $213,739 2024-11-14
Q2 2024 Added 93,953 +23,297 (33.0%) < 0.01% $695,252 2024-08-14
Q1 2024 Reduced 70,656 -28,891 (-29.0%) < 0.01% $553,236 2024-05-15
Q4 2023 Added 99,547 +51,261 (106.2%) < 0.01% $505,698 2024-02-13
Q3 2023 Reduced 48,286 -11,580 (-19.3%) < 0.01% $285,853 2023-11-15
Q2 2023 Reduced 59,866 -40,019 (-40.1%) < 0.01% $444,206 2023-08-14
Q1 2023 Added 99,885 +59,412 (146.8%) < 0.01% $943,914 2023-05-15
Q4 2022 Reduced 40,473 -9,699 (-19.3%) < 0.01% $431,037 2023-02-14
Q3 2022 Added 50,172 +1,517 (3.1%) < 0.01% $370,000 2022-11-14
Q2 2022 Added 48,655 +28,247 (138.4%) < 0.01% $234,000 2022-08-15
Q1 2022 Reduced 20,408 -10,161 (-33.2%) < 0.01% $104,000 2022-05-13
Q4 2021 Reduced 30,569 -13,403 (-30.5%) < 0.01% $184,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

53 managers reported ACTINIUM PHARMACEUTICALS INC for Q3 2026.

Managers reporting ACTINIUM PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD CAPITAL MANAGEMENT LLC Reduced 1,233,926 -4,376 < 0.01% $1,381,997 3 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 483,666 -30,914 < 0.01% $541,706 11 qtrs
ACADIAN ASSET MANAGEMENT LLC Reduced 480,996 -15,292 < 0.01% $537,000 9 qtrs
BlackRock Inc Reduced 390,970 -4,926 < 0.01% $437,886 9 qtrs
COMPASS FINANCIAL MANAGEMENT LLC Reduced 389,230 -211,000 0.05% $435,938 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 342,589 -37,902 < 0.01% $383,700 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Unchanged 324,945 0 < 0.01% $364,062 25 qtrs
TWO SIGMA INVESTMENTS LP Reduced 234,856 -24,323 < 0.01% $263,039 6 qtrs
VANGUARD FIDUCIARY TRUST CO Added 200,589 +39,063 < 0.01% $224,660 3 qtrs
GAGNON SECURITIES LLC Unchanged 182,142 0 0.04% $203,999 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
2,466

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.